Bidish Patel

Bidish Patel

Auto-generated profile, based on publicly available information

Bidish Patel

Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC. Significance: This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.

23 November 2023 in Blood
Verified
Journal Article
Closed access
PDF file
BPBidish Kumar Patel
Bidish Kumar Patel
MRMichael J. Raabe
Michael J. Raabe
ELEvan R. Lang
Evan R. Lang
YSYuhui Song
Yuhui Song
CLChenyue Lu
Chenyue Lu
ZDZachariah DeFilipp
Zachariah DeFilipp
Severe acute graft-versus-host disease (aGVHD) is associated with significant mortality and morbidity, especially in steroid-resistant (SR) cases. Spatial transcriptomic technology can elucidate tissue-based interactions in vivo and possibly identify predictors of treatment response. Tissue sections from 32 treatment-naïve patients with biopsy-confirmed lower gastrointestinal (GI) aGVHD were obtained. The GeoMx digital spatial profiler was used to capture transcriptome profiles of >18 000 genes from different foci of immune infiltrates, colonic epithelium, and vascular endothelium. Each tissue compartment sampled showed 2 distinct clusters that were analyzed for differential expression and spatially resolved correlation of gene signatures. Classic cell-mediated immunity signatures, normal differentiated epithelial cells, and inflamed vasculature dominated foci sampled from steroid-sensitive cases. In contrast, a neutrophil predominant noncanonical inflammation with regenerative epithelial cells and some indication of angiogenic endothelial response was overrepresented in areas from SR cases. Evaluation of potential prognostic biomarkers identified ubiquitin specific peptidase 17–like (USP17L) family of genes as being differentially expressed in immune cells from patients with worsened survival. In summary, we demonstrate distinct tissue niches with unique gene expression signatures within lower GI tissue from patients with aGVHD and provide evidence of a potential prognostic biomarker.

26 May 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZCZoe L Cosner
Zoe L Cosner
ZGZhoubo Guo
Zhoubo Guo
CNCole Nawrocki
Cole Nawrocki
BPBidish Patel
Bidish Patel
HRHannah J. Roberts
Hannah J. Roberts
JFJoseph Franses
Joseph Franses
Purpose: Although immunotherapy regimens have significantly improved treatment options for patients with advanced hepatocellular carcinoma (HCC), the optimal use of these regimens in earlier disease stages remains poorly defined. Patients and Methods: We conducted a single-institution, single-arm pilot study (NCT04857684) of neoadjuvant stereotactic body radiotherapy (SBRT) followed by 2 cycles of atezolizumab plus bevacizumab and subsequent surgical resection in patients with initially resectable HCC (n = 8). The primary endpoint was safety as defined by the proportion of patients with grade 3 to 4 treatment-related adverse events (trAE) by Common Terminology Criteria for Adverse Events v5.0. Furthermore, we dissected the detailed remodeling of the tumor immune microenvironment following treatment using single-cell resolution spatial transcriptomic method. Results: Only 1 patient experienced a grade 3 trAE. Seven of 8 patients proceeded to surgery, and all achieved margin-negative (R0) resection; 1 patient did not proceed because of subsequent disagreement of resectability. One patient achieved a pathologic complete response, and all resected patients were relapse-free at data cutoff (median follow-up, 16.3 months; range, 2.1–19.9). Compared with unmatched treatment-naïve HCC specimens, posttreatment specimens showed significantly higher anticancer immune infiltration, including organized peritumoral aggregates. Immune infiltration and its proximity to tumor cells correlated with preoperative radiographic response. Conclusions: This study provides proof of concept that neoadjuvant SBRT and immunotherapy is safe and provides a clear rationale for additional prospective clinical studies utilizing this strategy.

2 May 2025
Verified
Other
Open access
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.

17 July 2026
Verified
Other
Open access
ZCZoe L Cosner
Zoe L Cosner
ZGZhoubo Guo
Zhoubo Guo
CNCole Nawrocki
Cole Nawrocki
BPBidish Patel
Bidish Patel
HRHannah J. Roberts
Hannah J. Roberts
JFJoseph Franses
Joseph Franses
Supplementary Table S5 from Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment

17 July 2026
Verified
Other
Open access
ZCZoe L Cosner
Zoe L Cosner
ZGZhoubo Guo
Zhoubo Guo
CNCole Nawrocki
Cole Nawrocki
BPBidish Patel
Bidish Patel
HRHannah J. Roberts
Hannah J. Roberts
JFJoseph Franses
Joseph Franses
Figure S1. (A) Cross-sectional imaging showing baseline and pre-surgery CT scans of remaining patients that underwent both sets of imaging. Patients a-c had partial response per RECIST 1.1 criteria. Patients d-f had stable disease per RECIST 1.1 criteria. (B) Alpha fetoprotein (AFP), absolute lymphocyte count (ALC), white blood cell count (WBC), hemoglobin (Hgb), and platelet (PLT) count trends with time over the trial treatment duration. (C) Trends in individual trial participant tumor sizes before/after neoadjuvant therapy, assessed radiographically. (D) Duration of follow-up for each individual participant in the trial.